SANDOZ HERITAGE

Sandoz Is Committed to Developing Safe, Efficacious, and Accessible Medicines

As a pioneer in the development of biologics, Sandoz knows how life-changing these medicines can be. Sandoz has a rich heritage of biosimiliar development and is committed to continuing a strong tradition of biosimilar development and manufacturing.1

Sandoz: A pioneer and global leader in biosimilars

Global leader in biosimilars
40+

years of biologics manufacturing experience2

25+

years of biosimilar development1

15+

years of biosimilars in Europe3

11

total biosimilars in development or in market4-9

7

years of biosimilars in the US10

Sandoz is committed to bringing advanced, affordable medicines to market

Sandoz uses state-of-the-art manufacturing and analysis technologies to produce high-quality biosimilars. The Sandoz US portfolio includes a broad range of biosimilars with potential for significant cost savings.4-9, 11

What’s more, Sandoz provides robust support services, ensuring continuity of care for patients taking Sandoz biosimilars.
Therapeutic AreaIn DevelopmentFDA Approved
NEUROLOGY 41
ONCOLOGY 5-722
ENDOCRINOLOGY 83
IMMUNOLOGY 5,912
Rigorously developed and FDA approved<sup>12</sup>

Rigorously developed and FDA approved12

Learn how biosimilars are evaluated through a Food and Drug Administration (FDA) step-wise development process.

Proven safety and efficacy<sup>12</sup>

Proven safety and efficacy12

Understand the difference that quality, cost-effective biosimilars can make for patients living with neurological conditions.

Building a sustainable system<sup>13</sup>

Building a sustainable system13

See the savings that patients and the healthcare system can achieve with biosimilars.

Support Act4Biosimilars

Support Act4Biosimilars

Act4Biosimilars aims to close the gap and support making biologic medicines more available to all. Learn what you can do to support this mission.
Photos used are not of actual patients or healthcare professionals.
References
  1. What Lies Ahead for Biosimilars?. https://themedicinemaker.com/business-regulation/what-lies-ahead-for-biosimilars. Published August 12, 2021. Accessed July 28, 2022.
  2. Rios M. A decade of microbial fermentation. BioProcess International. https://bioprocessintl.com/upstream-processing/fermentation/a-decade-of-microbial-fermentation-331179/. Published June 1, 2012. Accessed March 13, 2018.
  3. European Medicines Agency. Omnitrope® Summary of Product Characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000607/WC500043695.pdf Accessed November 2021.
  4. Davio K. Sandoz to commercialize biosimilar of MS drug, natalizumab. https://www.centerforbiosimilars.com/view/sandoz-to-commercialize-biosimilar-of-ms-drug-natalizumab. Published September 3, 2019. Accessed May 18, 2022.
  5. U.S. Food & Drug Administration. Biosimilar Product Information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Accessed May 5, 2022.
  6. Jeremias S. https://www.centerforbiosimilars.com/view/phase-3-trial-demonstrates-bioequivalence-for-eirgenix-s-trastuzumab-biosimilar-candidate. Published March 27, 2021. Accessed August 18, 2021.
  7. Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine. Sandoz Website. https://www.sandoz.com/news/media-releases/sandoz-strengthens-pipeline-entering-agreement-biosimilar-bevacizumab-key. Accessed July 12, 2022.
  8. Sandoz enters into commercialization and supply agreement for insulin biosimilars, anticipating growing demand as diabetes burden rises. Sandoz Website. https://www.sandoz.com/news/media-releases/sandoz-enters-commercialization-and-supply-agreement-insulin-biosimilars. Published December 19, 2018. Accessed August 18, 2021.
  9. Davio K. https://www.centerforbiosimilars.com/view/sandoz-enrolls-first-patient-in-study-of-proposed-denosumab-biosimilar-gp2411. Published July 22, 2019. Accessed August 18, 2021.
  10. FDA approves first biosimilar product Zarxio [press release]. Rockville, MD: US Food and Drug Administration; March 6, 2015.
  11. McCamish M, Woollett G. Worldwide experience with biosimilar development. mAbs. 2011;3(2):209‑217. doi:10.4161/mabs.3.2.15005.
  12. U.S. Food & Drug Administration. Biosimilar Regulatory Review and Approval. https://www.https://www.fda.gov/media/151061/download#:~:text=Biosimilar%20Approval%20Process&text=FD. Accessed July 3, 2022.
  13. EHA 2018: can biosimilars be implemented worldwide to promote sustainability? Pharmaceutical Technology website. https://www.pharmaceutical-technology.com/comment/eha-2018-can-biosimilars-implemented-worldwide-promote-sustainability/. Published June 19, 2018. Accessed July 11, 2022.